<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39730380</article-id><article-id pub-id-type="pmc">PMC11681204</article-id><article-id pub-id-type="publisher-id">74236</article-id><article-id pub-id-type="doi">10.1038/s41598-024-74236-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Principal component analysis of the Serological response to <italic>Plasmodium Falciparum</italic> using a Multiplex bead-based assay in Nigeria</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schultz</surname><given-names>Jonathan S.</given-names></name><address><email>rix1@cdc.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Okoli</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>Colleen M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sayre</surname><given-names>Dean</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Heilig</surname><given-names>Charles M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Uhomoibhi</surname><given-names>Perpetua</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ogunniyi</surname><given-names>Abiodun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ndodo</surname><given-names>Nnaemeka</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mba</surname><given-names>Nwando</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Abubakar</surname><given-names>Ado G.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Akinmulero</surname><given-names>Oluwaseun</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dawurung</surname><given-names>Ayuba B.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Okoye</surname><given-names>McPaul</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Iriemenam</surname><given-names>Nnaemeka C.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Plucinski</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Steinhardt</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rogier</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ihekweazu</surname><given-names>Chickwe</given-names></name><address><email>chikwe.ihekweazu@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Epidemic Intelligence Service, </institution><institution>Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Division of Parasitic Diseases and Malaria, </institution><institution>Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff3"><label>3</label>Centre for Disease Control and Prevention, Abuja, FCT Nigeria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Center for Surveillance, Epidemiology, and Laboratory Services, </institution><institution>Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042twtr12</institution-id><institution-id institution-id-type="GRID">grid.416738.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2163 0069</institution-id><institution>Malaria Branch, </institution><institution>U.S. President&#x02019;s Malaria Initiative, U.S. Centers for Disease Control and Prevention, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff6"><label>6</label>National Malaria Elimination Programme, Abuja, FCT Nigeria </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02e66xy22</institution-id><institution-id institution-id-type="GRID">grid.421160.0</institution-id><institution>Institute of Human Virology Nigeria, </institution></institution-wrap>Abuja, FCT Nigeria </aff><aff id="Aff8"><label>8</label>Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abuja, FCT Nigeria </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><elocation-id>30658</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Characterization of serological responses to <italic>Plasmodium falciparum</italic> (<italic>Pf</italic>) is of interest to understand disease burden and transmission dynamics; however, their interpretation is challenging. Dried blood spots from 30,815 participants aged 6 months to 15 years from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey were analyzed by multiplex bead-based assay to measure immunoglobulin G (IgG) to <italic>Pf</italic>-stage-specific MSP-1, AMA-1, GLURPR0, LSA-1, and CSP. These IgG levels were analyzed by principal component analysis (PCA). PC1 and PC2 scores explained 41% and 17% of the total variance, respectively. PC1 unit vectors represented seropositivity. PC2 unit vectors for blood-stage antigens were in opposite directions to liver-stage and sporozoite antigens. PC2 scores were correlated with MSP-1 positively (R&#x02009;=&#x02009;0.52, P&#x02009;&#x0003c;&#x02009;0.001) and CSP negatively (R=-0.65, P&#x02009;&#x0003c;&#x02009;0.001) and may help identify areas with prior exposure but higher risk for increased infections or epidemics. PCA of <italic>Pf</italic> serology can provide summary scores to possibly inform future programmatic interventions.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-024-74236-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Plasmodium Falciparum</kwd><kwd>Nigeria</kwd><kwd>Serology</kwd><kwd>Multiplex bead-based assay (MBA)</kwd><kwd>Principal component analysis (PCA)</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Parasite host response</kwd><kwd>Epidemiology</kwd><kwd>Predictive markers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Progress against global malaria has stagnated over the past decade<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, and as a result the World Health Organization (WHO) now recommends that malaria-endemic countries tailor their interventions on a sub-national scale based on local disease burden and transmission dynamics<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. This approach aims to maximize intervention effectiveness through more efficient allocation of limited resources in national malaria strategic planning. Effective subnational tailoring depends on accurate measurement of malaria burden. However, accurate burden estimates throughout a malaria-endemic region or country can be challenging to acquire, particularly those at a more granular spatiotemporal scale. Disease burden estimates can provide valuable information to target interventions to intensify control efforts in high burden areas, maintain gains achieved, or implement elimination strategies in low transmission areas<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">Various metrics attempt to measure <italic>Plasmodium falciparum</italic> (<italic>Pf</italic>) burden including (1) parasite-based measures such as <italic>Pf</italic> parasite prevalence (<italic>Pf</italic>Pr), (2) clinical infection, severe disease and death incidence from routine data, (3) force of infection (FOI), (4) multiplicity of infection (MOI), (5) seroprevalence and seroconversion rates (SCR) from large cross-sectional surveys, and (6) vector-based measures such as the entomological inoculation rate (EIR) and vectorial capacity of <italic>Anopheles spp</italic><sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup>. <italic>Pf</italic>Pr from Demographic Health Surveys (DHS) or Malaria Indicator Surveys (MIS) is often considered the gold standard for disease burden, however it needs to be interpreted carefully. These surveys measure cross-sectional <italic>Pf</italic>Pr for active or recent malaria infections using microscopy or rapid diagnostic tests (RDT) and are typically conducted during peak transmission; however, the exact timing of peak cross-sectional <italic>Pf</italic>Pr can vary widely from year to year with changes in vector abundance<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Many countries are shifting away from using time- and resource-intensive microscopy during these surveys to RDTs. While easy to perform in the field, the validity of RDTs results is challenged by increasing reports of histidine rich protein-2 (HRP2) deletions, the main molecular target for RDTs, as well as HRP2 persistence after treatment<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. RDTs also have highly variable limits of detection and RDT positivity can vary greatly between and within surveys and between brands, making results difficult to compare<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par4">Routine data from malaria reporting systems can also be used to characterize malaria burden; however, routine surveillance systems do not represent the true burden of disease in many high burden countries due to asymptomatic infections, self-treatment, and care-seeking outside the public sector<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Additionally, incidence of malaria cases reported by routine surveillance data systems can be confounded by many other factors such as changes in access to care, availability of commodities for testing (RDTs or microscopy), population changes, challenges with reporting routine data as well as gathering and integration of complex national data<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par5">Other metrics for malaria burden such as FOI and MOI estimate the number of infections per person per time. FOI counts all patent incident malaria infections (symptomatic or asymptomatic) over time and MOI is the number of concurrent <italic>Pf</italic>clones per host measured by various complex genotyping techniques<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Seroprevalence and SCR are determined by collecting data on antibodies directed against a single or limited number of malaria antigens and creating a positivity threshold or fitting simple reverse catalytic models by age groups using maximum likelihood estimates<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. However, there are limitations in detecting small changes in transmission intensity or transmission heterogeneity in a population using these methods<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par6">Serological profiles to malaria antigens have been a useful tool to measure historical exposure and recent infection due to the differential half-lives and longevity of different antibodies against-malaria stage-specific antigens<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>; however, no single antibody or combination of antibodies has been established as a reliable marker of malarial disease burden, transmission dynamics, or populations at risk for epidemics<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>. In addition, multiplex bead-based assays (MBA) to measure levels of both malarial antigens and antibodies using dried blood spots (DBS) have been developed and validated and are increasingly being used in resource-limited settings to provide detailed serological information<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>. However, it can be difficult to simultaneously interpret and summarize data on multiple <italic>Pf</italic>-specific antibodies<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. The objective of this study was to evaluate how multiple antibody levels can be simplified using a principal component analysis (PCA) and results can be used for inferring disease burden and population at risks for epidemics.</p><p id="Par7">For this study, we utilized DBS samples collected from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) a nationally representative population-based HIV serosurvey<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref></sup>. We explored serologic profiles, using a PCA to simplify antibodies levels directed against five different <italic>Pf-</italic>stage-specific proteins: merozoite surface protein-1 (MSP-1), apical membrane antigen-1 (AMA-1), glutamate rich protein-0 (GLURP0), liver stage antigen-1 (LSA-1), and circumsporozoite protein (CSP). Antibody levels and PCA scores were mapped and compared by state. Individual PCA scores were evaluated against known malaria risk factors using univariate and multivariable survey-weighted linear regression models.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study area</title><p id="Par8">Nigeria is the most populous country in Africa with an estimated population of 223&#x000a0;million in 2023<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. The country is divided into 36 states and the Federal Capital Territory and organized into six geopolitical zones. All of Nigeria is endemic for <italic>Pf;</italic> the 2018 DHS estimated a national cross-sectional <italic>Pf</italic>infection prevalence of 36.2% by RDT and 22.6% by microscopy in children 6 to 59 months<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. The Sahel of northern Nigeria has seasonal <italic>Pf</italic>transmission while the south has more stable and persistent transmission<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p></sec></sec><sec id="Sec4"><title>Nigeria HIV/AIDS indicator and impact survey (NAIIS)</title><p id="Par9">In 2018, the Government of Nigeria conducted the NAIIS through the Federal Ministry of Health (FMoH) and the National Agency for the Control of AIDS, with technical support from the U.S. Centers for Disease Control and Prevention (CDC), Nigeria CDC, and the University of Maryland, Baltimore<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. The NAIIS was a nationally representative household-based survey to estimate the prevalence and incidence of HIV at state and national levels<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>. Survey methods have been previously described<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>; briefly, a stratified two-stage cluster sample design was used to construct a probability sample of 89,345 households, from which data and venous blood were collected from all consenting individuals aged 15 years and older. From a randomly sampled subset of 28,220 households, blood specimens from all resident children aged 0 to 15 years were also collected following informed consent from their parents. Specimen volume and collection method varied by age: a 14 mL venous blood specimen was collected from adults aged 15&#x02013;64 years, a 6 mL venous blood specimen was collected from children aged 2&#x02013;14 years and a 1 mL capillary blood specimen was collected from children aged&#x02009;&#x0003c;&#x02009;2 years, using a finger stick for children aged 6 to 23 months and a heel stick for infants below 6 months of age. For participants&#x02009;&#x02265;&#x02009;2 years who could not provide a venous blood specimen, blood was collected from a finger stick using the 1&#x000a0;ml ethylene diamine tetra acetic acid (EDTA) microtube. Data and blood samples were collected between July and December 2018, with data collection typically completed in less than one month in each state. Whole blood samples were used to create DBS within 24&#x000a0;h of collection and stored at -20&#x000a0;&#x000b0;C; within a week of collection they were transported to a central laboratory and stored at -80&#x000a0;&#x000b0;C<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p></sec><sec id="Sec5"><title>Nigeria multi-disease serologic surveillance using stored specimens (nms4)</title><p id="Par10">The NMS4 project was initiated to understand the burden of multiple diseases, including malaria, across all of Nigeria. DBS collected during the NAIIS were analyzed to quantitatively measure levels of <italic>Pf</italic> Histidine Rich Protein-2 (HRP2) antigen and human IgG antibodies directed against <italic>Pf-</italic>specific MSP-1, AMA-1, LSA-1, GLURP0 and CSP using the Luminex MAGPIX&#x02122; system (Luminex Corp, Austin, TX) at a target of 50 beads/region; individual median fluorescence intensities (MFI) were reported for each marker<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. HRP2 results for children from 6 to 59 months of age, non-<italic>Pf</italic>infections, among children under 15 years, and validation of the MBA in Nigeria have been previously described<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Children less than 6 months of age were excluded from this analysis to avoid confounding by maternal transplacental IgG. This study analyzed the previously measured raw IgG data.</p></sec><sec id="Sec6"><title>Ethical considerations</title><p id="Par11">All participants provided informed consent or assent before enrollment into the NAIIS survey. For children age&#x02009;&#x0003c;&#x02009;10 years, consent for biomarker testing and consent to future testing was granted by parent or guardian; assent was received from children aged 10&#x02013;14 years. Laboratory testing for malaria biomarkers as part of the NMS4 project was approved by the National Health Research Ethics Committee of Nigeria (NHREC/01/01/2007) as part of the Government of Nigeria under the Federal Ministry of Health and determined to not involve human research by the Centers for Disease Control and Prevention Human Subjects office (project 0900f3eb819d4c63). All methods were performed in accordance with the relevant guidelines and regulations of the NAIIS survey and NMS4 protocols.</p></sec><sec id="Sec7"><title>Multiplex bead-based assay</title><p id="Par12">Purified recombinant antigens were covalently linked to xMAP microspheres (Luminex Corp, Austin, TX), as described previously<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The five antigens were utilized for all surveys: <italic>Pf</italic>recombinant MSP-1 (19kD fragment, coupled at pH 5 at 20&#x000a0;&#x000b5;g/mL)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>; and recombinant AMA-1 (N-terminal region, coupled at pH 5 at 20&#x000a0;&#x000b5;g/mL)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, GLURP0 (R0 region peptide coupled at pH 5 at 30 ug/ml)<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, LSA-1 (Pl1043 epitope peptide, coupled at pH 5 at 60&#x000a0;&#x000b5;g/mL)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>; CSP (NANP repeat peptide, coupled at pH 5 at 60 ug/mL)<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. These five <italic>Pf</italic>antigens have been widely used for previous malaria serological studies by multiple groups, and represent the evaluation of long-term IgG responses (MSP1 19kD region, AMA1 N-terminal region)<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref></sup>, as well as shorter host IgG responses (GLURP0, CSP and LSA-1)<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. For <italic>Pf</italic> HRP2/3 antigen detection monoclonal IgM and IgG antibodies were covalently bonded to polystyrene BioPlex<sup>&#x000ae;</sup>COOH beads (BioRad; 1715060XX) by the commonly-used EDC/Sulfo-NHS intermediate reaction and previously described in detail<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><sec id="Sec8"><title>Statistical analysis</title><p id="Par13">Descriptive statistics compared the five different <italic>Pf</italic>-specific IgG MFI levels by participant demographics, household characteristics, and state of residence. Continuous MFI levels were dichotomized using Otsu&#x02019;s method to maximize the inter-class variance by optimizing the separability of the resultant classes as positive or negative for each IgG and HRP2<sup><xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>. The PCA was used to discover pattens in the data and simplify the multiple IgG levels into composite principal component (PC) scores for each participant accounting for survey design weights (svyprcomp in R). PC unit vectors of the five IgG levels were projected onto PC1 versus PC2 space and PC2 versus PC3 space. Bivariate associations were explored between PC scores and known malaria risk factors such as participant and household characteristics (i.e., age, sex, urban vs. rural location, bed net ownership, number of bed nets, and wealth quintile), and month of sample collection. Correlations between individual PC scores versus individual IgG levels were evaluated. State mean PC1 and PC2 scores were plotted versus state mean HRP2 level and state proportion of urban participants. A survey-weighted linear regression model (svydesign and svyglm in R) was used to compare participant PC scores with traditional malaria risk factors. R version 4.2.2 was used for all analyses.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Plasmodium falciparum MBA serological analysis</title><p id="Par14">Among the 206,210 total participants in NAIIS, 31,800 (15.4%) were aged 6 months to 15 years. Of these, data on all malaria-specific IgG levels were available from 30,815; these are included in the analysis. Basic demographics showed that 18,610 individuals (58.5%) lived in rural areas and 11,636 individuals (36.6%) did not sleep under a mosquito net the night prior to the household survey (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Using Otsu&#x02019;s method for dichotomization 20.3% (95% CI 19.9&#x02013;20.8%) were positive for HRP2 antigen, 32.4% (95% CI 31.9% &#x02212;&#x02009;32.9%) were positive for anti-MSP-1 IgG, 49.6% (95% CI 49.0% &#x02212;&#x02009;50.2%) were positive for anti-AMA IgG, 5.4% (95% CI 5.2% &#x02212;&#x02009;5.7%) were positive for anti-GLURP0 IgG, 10.2% (95% CI 9.83% &#x02212;&#x02009;10.5%) were positive for anti-LSA IgG, and 2.9% (95% CI 2.7% &#x02212;&#x02009;3.0%) were positive for anti-CSP IgG(Supplemental Table 1). Mean MSP-1 and AMA-1 levels were over ten times higher than mean GLURP, LSA, and CSP levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Supplemental Table 1). Levels of all <italic>Pf</italic>-specific antibodies increased with participant age, though at different rates (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The fastest increase was seen for MSP-1 and AMA-1 IgG. Month of DBS sample collection was significantly associated (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) with all five IgG levels (Supplemental Fig.&#x000a0;1). Median levels of IgG for five antigens showed high geographical variability with the highest mean IgG levels in the Northwest and North Central geopolitical zones (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par15">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Numbers and characteristics of participants 6 months to 15 years of age among the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">Total</th><th align="left">%</th></tr></thead><tbody><tr><td align="left">Number of Participants</td><td char="." align="char">31,800</td><td char="." align="char">100.0</td></tr><tr><td align="left">&#x0003c;&#x02009;5 years</td><td char="." align="char">9,231</td><td char="." align="char">29.0</td></tr><tr><td align="left">5 to &#x0003c;&#x02009;15 years</td><td char="." align="char">22,569</td><td char="." align="char">71.0</td></tr><tr><td align="left">Female (N, %)</td><td char="." align="char">15,579</td><td char="." align="char">49.0</td></tr><tr><td align="left">Male (N, %)</td><td char="." align="char">16,221</td><td char="." align="char">51.0</td></tr><tr><td align="left">Rural (N, %)</td><td char="." align="char">18,610</td><td char="." align="char">58.5</td></tr><tr><td align="left">Urban (N, %)</td><td char="." align="char">13,190</td><td char="." align="char">41.5</td></tr><tr><td align="left">July (N, %)</td><td char="." align="char">2,805</td><td char="." align="char">8.8</td></tr><tr><td align="left">August (N, %)</td><td char="." align="char">5,277</td><td char="." align="char">16.6</td></tr><tr><td align="left">September (N, %)</td><td char="." align="char">6,200</td><td char="." align="char">19.5</td></tr><tr><td align="left">October (N, %)</td><td char="." align="char">6,514</td><td char="." align="char">20.5</td></tr><tr><td align="left">November (N, %)</td><td char="." align="char">6,632</td><td char="." align="char">20.9</td></tr><tr><td align="left">December (N, %)</td><td char="." align="char">4,357</td><td char="." align="char">13.7</td></tr><tr><td align="left">No bed net used in household</td><td char="." align="char">11,636</td><td char="." align="char">36.6</td></tr><tr><td align="left">One or more bed net used in household</td><td char="." align="char">20,156</td><td char="." align="char">63.4</td></tr><tr><td align="left">
<italic>Number of LLIN in household</italic>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">11,636</td><td char="." align="char">36.6</td></tr><tr><td align="left">1</td><td char="." align="char">3,732</td><td char="." align="char">11.7</td></tr><tr><td align="left">2</td><td char="." align="char">6,146</td><td char="." align="char">19.3</td></tr><tr><td align="left">3</td><td char="." align="char">3,786</td><td char="." align="char">11.9</td></tr><tr><td align="left">4</td><td char="." align="char">2,853</td><td char="." align="char">9.0</td></tr><tr><td align="left">5</td><td char="." align="char">1,478</td><td char="." align="char">4.6</td></tr><tr><td align="left">6</td><td char="." align="char">919</td><td char="." align="char">2.9</td></tr><tr><td align="left">7</td><td char="." align="char">1,242</td><td char="." align="char">3.9</td></tr><tr><td align="left">
<italic>Wealth Quintile</italic>
</td><td align="left"/><td align="left"/></tr><tr><td align="left">Lowest</td><td char="." align="char">6,765</td><td char="." align="char">21.3</td></tr><tr><td align="left">Second</td><td char="." align="char">6,595</td><td char="." align="char">20.7</td></tr><tr><td align="left">Middle</td><td char="." align="char">6,619</td><td char="." align="char">20.8</td></tr><tr><td align="left">Fourth</td><td char="." align="char">6,369</td><td char="." align="char">20.0</td></tr><tr><td align="left">Highest</td><td char="." align="char">5,452</td><td char="." align="char">17.1</td></tr></tbody></table></table-wrap>
</p><p id="Par16">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Histograms and age distributions of five IgG antibodies against <italic>Plasmodium falciparum</italic> antigens. (A-E) Histograms with positivity cutoffs (red verticle line) using Otsu&#x02019;s method and (F-J) box plots of mean fluorescent intensity (MFI) levels of five IgG antibodies against Plasmodium falciparum ( Pf ) antigens ( Pf MSP1, Pf AMA1, Pf LSA1, Pf GLURP0, Pf CSP) by age using a multiplex bead-based assay (MBA) among 30,812 participants aged 6 months to 15 years of age from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) in 2018. Footnote: Boxplot center line represents the median, box edges represent the 25th and 75th percentiles, whiskers extend up to 1.5 * IQR.</p></caption><graphic xlink:href="41598_2024_74236_Fig1_HTML" id="d33e939"/></fig>
</p><p id="Par17">
<fig id="Fig2"><label>Fig. 2</label><caption><p>State median histidine rich protein-2 (HRP2) and median IgG levels to <italic>Plasmodium falciparum</italic> antigens (<italic>Pf</italic>MSP1, <italic>Pf</italic>AMA1, <italic>Pf</italic>LSA1, <italic>Pf</italic>GLURP0, <italic>Pf</italic>CSP) from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS).</p></caption><graphic xlink:href="41598_2024_74236_Fig2_HTML" id="d33e969"/></fig>
</p></sec><sec id="Sec11"><title>Principal component analysis</title><p id="Par18">Five PC scores were generated using the five IgG MFI levels for each participant. PC1 accounted for 41.2% of the total IgG variance and PC2 and PC3 explained an additional 17.4% and 16.6% of the variance, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). PC4 and PC5 accounted for the remaining 12.6% and 12.2% of the total variance in these data, respectively. All PC1 unit vectors on the x-axis had the same directionality and similar magnitudes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Individual PC1 and PC2 increased significantly with participant age (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> Supplemental Fig.&#x000a0;2). State mean PC1 score was positively associated with mean HRP2 level (<italic>R</italic>&#x02009;=&#x02009;0.76, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Supplemental Fig.&#x000a0;3A). State mean PC1 scores were negatively correlated with increasing proportion of urban participants (<italic>R</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.34, <italic>p</italic>&#x02009;=&#x02009;0.04) (Supplemental Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Individual PC1 scores were positively correlated with all individual <italic>Pf</italic> IgG levels (<italic>R</italic>&#x02009;=&#x02009;0.61, <italic>R</italic>&#x02009;=&#x02009;0.69, <italic>R</italic>&#x02009;=&#x02009;0.72, <italic>R</italic>&#x02009;=&#x02009;0.54, <italic>R</italic>&#x02009;=&#x02009;0.50, all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, for MSP-1, AMA-1, GLURP0, LSA-1 and CSP, respectively) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A-E).<fig id="Fig3"><label>Fig. 3</label><caption><p>Principal Component Analysis of five anti-<italic>Plasmodium falciparum</italic> IgG levels.&#x000a0;(<bold>A</bold>) Percent variance of the mean fluorescent intensity (MFI) levels of five IgG antibodies against Plasmodium falciparum antigens (MSP-1, AMA-1, LSA-1, GLURP0, CSP) explained by each principal component (PC) among 30,812 participants aged 6 months to 14 years of age from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) in 2018. (<bold>B</bold> and <bold>C</bold>) PC loadings for the first three principal components show the PC unit vectors of the mean fluorescent intensity (MFI) levels of five IgG antibodies against Plasmodium falciparum antigens antibodies projected onto PC1 vs. PC2 and PC2 vs. PC3 space.</p></caption><graphic xlink:href="41598_2024_74236_Fig3_HTML" id="d33e1048"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Mean principal component (PC) scores PC1 (<bold>A</bold>) and PC2 (<bold>B</bold>) by state using data from the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) assayed for <italic>Plasmodium falciparum</italic> antibodies.</p></caption><graphic xlink:href="41598_2024_74236_Fig4_HTML" id="d33e1065"/></fig></p><p id="Par19">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Survey-weighted general linear regression model for univariate and multivariable predictors for individual principal component scores [PC1 and PC2].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">
<bold>Characteristic</bold>
</th><th align="left" colspan="6">PC1</th><th align="left" colspan="6">PC2</th></tr><tr><th align="left" colspan="3">
<bold>Univariate (PC1)</bold>
</th><th align="left" colspan="3"><bold>Multivariable (PC1)</bold> *</th><th align="left" colspan="3">
<bold>Univariate (PC2)</bold>
</th><th align="left" colspan="3"><bold>Multivariable (PC2)</bold> *</th></tr><tr><th align="left">
<bold>Beta</bold>
</th><th align="left">
<bold>95% CI</bold>
<sup>1</sup>
</th><th align="left">
<bold>p-value</bold>
</th><th align="left">
<bold>Beta</bold>
</th><th align="left">
<bold>95% CI</bold>
<sup>1</sup>
</th><th align="left">
<bold>p-value</bold>
</th><th align="left">
<bold>Beta</bold>
</th><th align="left">
<bold>95% CI</bold>
<sup>1</sup>
</th><th align="left">
<bold>p-value</bold>
</th><th align="left">
<bold>Beta</bold>
</th><th align="left">
<bold>95% CI</bold>
<sup>1</sup>
</th><th align="left">
<bold>p-value</bold>
</th></tr></thead><tbody><tr><td align="left">Age (continuous)</td><td align="left">0.11</td><td align="left">0.10, 0.11</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.11</td><td align="left">0.11, 0.12</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.01</td><td align="left">0.00, 0.01</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.01</td><td align="left">0.00, 0.01</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Age (&#x02009;&#x0003e;&#x02009;=&#x02009;5 years)</td><td align="left">0.72</td><td align="left">0.68, 0.75</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">0.07</td><td align="left">0.05, 0.09</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td></tr><tr><td align="left">Female</td><td align="left">-0.06</td><td align="left">-0.10, -0.03</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.07</td><td align="left">-0.10, -0.04</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.00</td><td align="left">-0.02, 0.02</td><td align="left">0.9</td><td align="left">0.00</td><td align="left">-0.02, 0.02</td><td align="left">&#x0003e;&#x02009;0.9</td></tr><tr><td align="left">Urban Residence</td><td align="left">-0.65</td><td align="left">-0.72, -0.59</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.33</td><td align="left">-0.41, -0.25</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.06</td><td align="left">-0.10, -0.03</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.00</td><td align="left">-0.04, 0.04</td><td align="left">0.8</td></tr><tr><td align="left">Collection Month *</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">July (reference)</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td></tr><tr><td align="left">August</td><td align="left">0.46</td><td align="left">0.08, 0.85</td><td align="left">0.02</td><td align="left">0.39</td><td align="left">0.07, 0.72</td><td align="left">0.02</td><td align="left">-0.14</td><td align="left">-0.34, 0.05</td><td align="left">0.2</td><td align="left">-0.14</td><td align="left">-0.34, 0.05</td><td align="left">0.15</td></tr><tr><td align="left">September</td><td align="left">-0.13</td><td align="left">-0.31, 0.04</td><td align="left">0.13</td><td align="left">-0.18</td><td align="left">-0.32, -0.04</td><td align="left">0.01</td><td align="left">-0.16</td><td align="left">-0.24, -0.08</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.05</td><td align="left">-0.24, -0.07</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">October</td><td align="left">-0.08</td><td align="left">-0.23, 0.06</td><td align="left">0.3</td><td align="left">-0.11</td><td align="left">-0.23, 0.00</td><td align="left">0.06</td><td align="left">0.03</td><td align="left">-0.05, 0.1</td><td align="left">0.5</td><td align="left">-0.02</td><td align="left">-0.05, 0.10</td><td align="left">0.5</td></tr><tr><td align="left">November</td><td align="left">-0.05</td><td align="left">-0.17, 0.06</td><td align="left">0.4</td><td align="left">-0.03</td><td align="left">-0.13, -0.07</td><td align="left">0.5</td><td align="left">0.02</td><td align="left">-0.04, 0.08</td><td align="left">0.5</td><td align="left">-0.02</td><td align="left">-0.04, 0.08</td><td align="left">0.5</td></tr><tr><td align="left">December</td><td align="left">0.01</td><td align="left">-0.11, 0.12</td><td align="left">0.9</td><td align="left">0.05</td><td align="left">-0.05, 0.14</td><td align="left">0.3</td><td align="left">-0.04</td><td align="left">-0.1, 0.02</td><td align="left">0.2</td><td align="left">-0.04</td><td align="left">-0.10, 0.02</td><td align="left">0.2</td></tr><tr><td align="left">Net ownership</td><td align="left">0.11</td><td align="left">0.06, 0.16</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">0.05</td><td align="left">0.02, 0.07</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td></tr><tr><td align="left">Number of Nets</td><td align="left">0.05</td><td align="left">0.04, 0.07</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.01</td><td align="left">-0.01, 0.02</td><td align="left">0.2</td><td align="left">0.02</td><td align="left">0.01, 0.03</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.01</td><td align="left">0.00, 0.01</td><td align="left">0.2</td></tr><tr><td align="left">Wealth Quintile</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">1 (Low)</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left">&#x02014;</td><td align="left"/></tr><tr><td align="left">2</td><td align="left">-0.32</td><td align="left">-0.40, -0.24</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.27</td><td align="left">-0.34, -0.19</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.01</td><td align="left">-0.04, 0.06</td><td align="left">0.8</td><td align="left">0.01</td><td align="left">-0.03, 0.06</td><td align="left">0.6</td></tr><tr><td align="left">3</td><td align="left">-0.52</td><td align="left">-0.60, -0.43</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.47</td><td align="left">-0.56, -0.37</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">0.00</td><td align="left">-0.05, 0.05</td><td align="left">&#x0003e;&#x02009;0.9</td><td align="left">0.00</td><td align="left">-0.04, 0.05</td><td align="left">0.7</td></tr><tr><td align="left">4</td><td align="left">-0.84</td><td align="left">-0.93, -0.76</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.72</td><td align="left">-0.82, -0.62</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.04</td><td align="left">-0.09, 0.01</td><td align="left">0.2</td><td align="left">-0.04</td><td align="left">-0.06, 0.05</td><td align="left">0.7</td></tr><tr><td align="left">5 (High)</td><td align="left">-1.2</td><td align="left">-1.3, -1.2</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-1.0</td><td align="left">-1.1, -0.91</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.20</td><td align="left">-0.25, -0.15</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">-0.20</td><td align="left">-0.19, -0.07</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="13"><sup>1</sup>CI = Confidence Interval. * = Collection month was controlled for by state in univariate analysis. Multivariable model also controlled for state. &#x02013; = Indicates the reference group for age, collection month, and wealth quintile in the multivariable models.</td></tr></tbody></table></table-wrap>
</p><p id="Par20">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Individual PC1 and PC2 scores versus anti-<italic>Plasmodium falciparum</italic> IgG levels.&#x000a0;(<bold>A</bold>&#x02013;<bold>E</bold>) Individual PC1 and (<bold>F</bold>&#x02013;<bold>J</bold>) PC2 versus anti-<italic>Plasmodium falciparum</italic> IgG levels (MSP-1, AMA-1, GLURP0, LSA-1 and CSP), with linear regression lines, Pearson correlation coefficients and p-values.</p></caption><graphic xlink:href="41598_2024_74236_Fig5_HTML" id="d33e1748"/></fig>
</p><p id="Par21">PC2 unit vectors on the y-axis grouped antibodies directed against the erythrocytic cycle antigens (MSP-1 and AMA-1) opposite to the sporozoite (CSP) and hepatocyte (LSA-1) antigens. Thus, PC2 represented the approximate difference between an average of MSP-1 and AMA-1 and an average of CSP and LSA-1 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B and C). State mean PC2 scores were not significantly associated with mean state HRP2 level (<italic>R</italic>&#x02009;=&#x02009;0.16, <italic>p</italic>&#x02009;=&#x02009;0.34) (Supplemental Fig.&#x000a0;3B), but were negatively correlated with increasing proportion of urban participants (<italic>R</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.33, <italic>p</italic>&#x02009;=&#x02009;0.04) (Supplemental Fig.&#x000a0;4B). Individual PC2 scores were positively correlated with all individual MSP-1 (<italic>R</italic>&#x02009;=&#x02009;0.52) and AMA-1 (<italic>R</italic>&#x02009;=&#x02009;0.23), and negatively associated with LSA-1 (<italic>R</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.35) and CSP (<italic>R</italic> = -0.65) all significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">5</xref>F-J). States in the North West and North Central regions had higher mean PC1 scores (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">4</xref>A). States with major urban centers of Lagos and Abuja had lower mean PC1 and PC2 scores (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">4</xref>A-B and Supplemental Fig.&#x000a0;4A-B).</p></sec><sec id="Sec12"><title>Regression analysis of PC scores</title><p id="Par22">In the univariate survey-weighted general linear regression analysis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), increasing age, male sex, rural residence, net ownership, and number of nets were all significantly associated with higher PC1 scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Increasing wealth quintile was associated with lower PC1 scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). These relationships were maintained when all were included in the multivariable model. The univariate survey-weighted linear regression model for PC2 showed that increasing age, number of nets, and net ownership were significantly associated with higher PC2 scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Highest wealth quintile was statistically associated with lower PC2 scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). In contrast, sex was not significantly associated with PC2 scores. When including all predictors in the multivariate model, increasing age, sample collection in September (<italic>p</italic>&#x02009;=&#x02009;0.01) compared to July (reference), and highest wealth quintile compared to lowest (reference group) remained statistically associated with lower PC2 scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), while adjusting for state.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p id="Par23">This study evaluated HRP2 antigen and five <italic>Pf</italic> stage-specific IgG antibodies (MSP-1, AMA-1, GLURP0, LSA-1, and CSP) among 30,815 participants aged 6 months to 15 years of age from one of the largest household surveys ever completed. Utilizing malaria immunology knowledge and PCA, an unsupervised learning technique to identify pattens in these complex and correlated serological data, we were able to simplify five serological levels into two meaningful scores that could be applied to a population level and be informative for public health interventions. These PC summary scores could be helpful to identify areas with the highest <italic>Pf</italic>disease burden (PC1) and evidence of prior but not recent infections (PC2) for targeted interventions recommended in sub-national stratification methods by the WHO<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Multiple prior malaria serological surveys in malaria endemic countries could possibly benefit from similar PCA analysis of these complex serological data and provide reproducibility on the general PC conclusions<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>.</p><sec id="Sec14"><title>MBA levels and dichotomization</title><p id="Par24">Given the high sensitivity of MBA to detect targets and skewed distribution of serological data, a novel approach using Otsu&#x02019;s method was used to dichotomize a continuous MFI to determine if a participant was considered positive or negative. Otsu&#x02019;s method has been primarily used in image thresholding to determine the optimal threshold that provides the largest absolute Student&#x02019;s t-statistic or maximizing the inter-class variance<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Creating cutoffs for positivity in serological data can be done using several approaches, including using the mean from known seronegative samples, and adding two or three standard deviations, or using finite mixture models to identify a presumed seronegative sub-population within the sample and then taking the mean plus two or three standard deviations<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Finite mixture models were previously used to dichotomize HRP2 levels in children 6&#x02013;59 months of age resulting in a seropositivity of 38.3% (36.7&#x02013;39.9%) by NAIIS DBS, however Otsu&#x02019;s method resulted in 20.3% (19.9-20.8%) which is much closer to the 22.6% (95% CI 21.2&#x02013;24.1%) via microscopy found in the 2018 DHS<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, and which may be more clinically relevant in this population. High quality microscopy capacity can be challenging to maintain and can have limited sensitivity missing some infections compared to molecular methods. In addition, advantage of Otsu&#x02019;s method doesn&#x02019;t require a set of true negative samples that are often not available<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> in malaria endemic area. More research is needed to evaluate Otsu&#x02019;s method or other machine learning techniques to determine the optimal threshold that maximizes the inter-class variance and provides the most relevant cutoffs for malaria serology, however Otsu&#x02019;s method appeared to be an appropriate in the current study.</p></sec><sec id="Sec15"><title>Pc1 interpretation</title><p id="Par25">PCA unit vectors corresponding to the five IgGs projected onto PC1 vs. PC2 space (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B) showed that from the PC1 perspective (or x-axis) all the unit vectors were unidirectional suggesting that participants with positive PC1 scores have a higher IgG level or a presence of malaria antibody (prior exposure to malaria). Thus, PC1 described seropositivity as it dichotomized those with and without a serological response to the five measured <italic>Pf</italic> specific IgGs. Individual PC1 scores were positively correlated with all individual <italic>Pf</italic> stage-specific IgG levels and state mean PC1 scores were positively associated with state mean HRP2 MFI levels (<italic>p</italic>&#x0003c;&#x02009;0.001). As expected, bivariable and multivariable models demonstrated that known malaria risk factors were associated with PC1 or malaria seropositivity. PC1 scores could be interpreted as the percent of the population whose immune system has been exposed to malaria including historic or active and recent infections. PC1 scores may be more important for areas with lower transmission and consideration for elimination strategies as MSP-1 and AMA-1 IgG levels stay elevated in the body for longer periods of time compared to LSA-1 and CSP levels<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Since PC1 represented overall seropositivity, it was associated with other known predictors of prior malaria infections such as increasing age, male sex, living in a rural area, net ownership and number of bed nets owned in univariate and were maintained in multivariable regression models. Geographically the IgG levels and resulting PC1 scores by state showed higher levels in the North West and North Central regional zones which is consistent with median HPR2 levels and previously reported malaria prevalence in 2018<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p></sec><sec id="Sec16"><title>Pc2 interpretation</title><p id="Par26">PCA unit vectors from the PC2 (y-axis of Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B) perspective differentiated antigens expressed primarily during the parasite&#x02019;s erythrocytic stage (MSP-1 and AMA-1) from those expressed on non-erythrocytic stages, sporozoite (CSP) or by infected hepatocytes (LSA-1). PC2 could thus help differentiate those with prior erythrocytic infection (MSP-1 and AMA-1 response) to those with repeated sporozoite exposure from repeated infectious bites (CSP response) and liver stage infections (LSA-1 response). Areas with higher PC2 scores had higher median levels of MSP-1, but lower levels of LSA-1 and CSP, which require boosting from recent infections, suggesting existing immunity, but less recent infectious bites for boosting. Short half-lives of MSP-1 and AMA-1 of 9.8 days (95% CI 7.6&#x02013;12.0) have been described in young children with primary infections<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, however after recurrent boosting in high transmission settings the half-life of MSP-1 has been estimated to be 49.8 years (95% CI 35.4&#x02013;72.7)<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Additionally, seroconversion of MSP-1 and AMA-1 occurs after few infections and is well maintained in the absence of reinfection and may be most useful in areas of low endemicity<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Thus, those with higher CSP and LSA-1 responses compared to their MSP-1 and AMA-1 responses are likely being exposed to numerous recurrent infectious bites and resulting infections to mount a robust immune response which represents a marker of more recent infection or recurrent infections<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Importantly, the state mean PC2 scores were not associated with state mean HRP2 MFI levels. Thus, PC2 likely differentiates those with recent or multiple recurrent infections to mount a robust response or higher IgG level to antigens expressed on the sporozoite (CSP) and infected hepatocytes (LSA-1), to those with more remote infections (MSP-1 and AMA-1). Higher PC2 scores thus represent high MSP-1 and AMA-1, but lower LSA-1 and CSP, indicating prior exposures but no recent infections. In addition, dissecting the median difference between MSP-1 and CSP levels by state could possibly be helpful in identifying locations with previous high burden of disease but no recent infections, and therefore at risk of possible epidemics as sorted by the difference of these levels (Supplemental Fig.&#x000a0;5). Higher PC2 scores likely represented prior immunity but lack of recent infections, (high MSP1, low LSA-1, low CSP), and were also associated with known predictors of prior malaria infections such as increasing age, male sex, living in a rural area, net ownership, and number of bed nets owned in univariate analysis. Age, number of bed nets, and highest wealth quintile compared to lowest (reference) remained statistically significant in multivariable regression models of PC2. Mapping of mean PC2 scores by state and graphs of individual PC2 vs. IgG levels also supported the conclusion that those with higher PC2 scores had higher MSP-1, but lower LSA-1 and CSP-1 which require boosting from recent infections. Thus, PC2 scores could be used to identify locations with history of moderate or high endemicity, but possible relatively fewer recent infections. Thus, areas with high PC2 scores could identify epidemic prone areas. Additionally, those areas with high PC1 scores (seropositivity) but low PC2 scores (high LSA-1, high CSP) could benefit from strengthened malaria control strategies. The biological plausibility of PC3 results were challenging to interpret and not included in descriptive or regression analyses (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C).</p></sec><sec id="Sec17"><title>Limitations</title><p id="Par27">This study was cross sectional but collected samples over seven months. Given the variable and seasonal burden of <italic>Pf</italic> in the Sahel of Northern Nigeria, collecting samples at the same time could have improved the internal validity of this study, but it would have been logistically difficult to implement given the large sample size of this study. To address this concern, geographic location (State) was controlled for in the univariate and multivariable survey-weighted linear regression models. The NAIIS was designed for HIV prevalence estimates and lacked data collection specific to malaria-related behaviors and history of prior infections. The MBA measurements of MSP-1 and AMA-1 likely saturated the assay limits for some participants and could be improved with assay adjustment or serial dilution in future studies. Although the NAIIS provided a large sample size and diverse geographic distribution it is unclear how the PCA would perform in other settings and could result in different PCA interpretations. Lastly, DHS and MIS do not routinely collect DBS samples and thus additional comparisons regarding logistics and costs of sample collection are needed to fully understand the benefit of serological profiles to current approaches.</p></sec><sec id="Sec18"><title>Future opportunities</title><p id="Par28">Samples collected during national household surveys, such as the NAIIS, are being increasingly used to evaluate multiple pathogens and allow for collaboration between national surveillance programs. Strengthening laboratory capacity to perform multiplex serological assays could allow additional methods to strengthen surveillance and could help inform national programmatic decisions. Additional research is needed to evaluate using PCA of serological responses to <italic>Pf</italic> in areas of different malaria burden and how PC scores relate to future outbreaks and in low transmission or pre-elimination settings.</p></sec></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusions</title><p id="Par29">Understanding the burden of malaria in a diverse and heterogenous country like Nigeria is challenging; however, leveraging malaria serology and dimensionality reduction techniques such as PCA can help describe malaria disease burden. Serological responses to multiple <italic>Pf</italic> antigens can clarify the intensity of prior malaria exposures and risk of possible future epidemics in high-risk areas with waning immunity. Further research is needed to evaluate PCA on multiple serological markers of malaria in other countries. However, this exploratory analysis demonstrates the use of PCA on multiple <italic>Pf-</italic>specific antigen responses derived from an MBA that could be used in the future to help direct public health interventions to prevent and control malaria.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2024_74236_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the contribution of specimens by the NAIIS Group, including the Federal Ministry of Health (FMoH) Nigeria, National Agency for the Control of AIDS (NACA), National Population Commission (NPopC), National Bureau of Statistics (NBS), U.S. Centers for Disease Control and Prevention (CDC), The Global Funds to Fight AIDS, Tuberculosis, and Malaria, University of Maryland Baltimore (UMB), ICF International, African Field Epidemiology Network (AFENET), University of Washington (UW), the Joint United Nations Programme on HIV and AIDS (UNAIDS), World Health Organization (WHO), and United Nations Children&#x02019;s Fund (UNICEF). NAIIS was supported by the President&#x02019;s Emergency Plan for AIDS Relief (PEPFAR) through CDC under the cooperative agreement #U2GGH002108 to UMB and by the Global Funds to Fight AIDS, Tuberculosis, and Malaria through NACA, under the contract # NGA-H-NACA to UMB. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the NAIIS Group. The authors would also like to acknowledge the NMS4 technical working group, composed of: Oluwaseun O. Akinmulero, Andrew Thomas, Ayuba Dawurung, Mudiaga Eseikpe, Abubakar Bichi Iliyasu, Nengi Israel, Erasogie Evbuomwan, Chimaoge Achugbu, Mary Okoli, Nnaemeka Ndodo. The NMS4 was financed by contributions by the President&#x02019;s Emergency Plan for AIDS Relief (PEPFAR), the US President&#x02019;s Malaria Initiative, the Global Immunization Division of the US Centers for Disease Control and Prevention, and The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the Bill and Melinda Gates Foundation through CDC Foundation.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>AO, PU, AA, NCI, and MO were involved with protocol formation and survey execution. AA, MO, and ER coordinated laboratory work. JS analyzed data. SL, CS, DS and CH provided analytical, and methods support. JS, DS, MP, ER, and LS drafted the manuscript. All authors approved final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The NMS4 project was financed by contributions from the President&#x02019;s Emergency Plan for AIDS Relief (PEPFAR), the US President&#x02019;s Malaria Initiative, the Global Immunization Division of the US Centers for Disease Control and Prevention, and The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the Bill and Melinda Gates Foundation through CDC Foundation.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data availability: NMS4 data are owned by the Government of Nigeria (GoN); requests for NMS4 data must be approved by GoN and all other NMS4 principal investigators. Inquiries should be directed to the corresponding authors.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par30">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>CDC disclaimer</title><p id="Par31">The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World malaria report 2022. Geneva: World Health Organization, (2022).</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Global technical strategy for. <italic>Malaria 2016&#x02013;2030, 2021 Update</italic> (Geneva World Health Organization, 2021).</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Partnership to End Malaria. <italic>High Burden to high Impact: A Targeted Malaria Response</italic> (Geneva World Health Organization, 2018).</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Use of different transmission metrics to describe malaria epidemiology in the highlands of western Kenya</article-title><source>Malar. J.</source><year>2015</year><volume>14</volume><fpage>418</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0944-4</pub-id><pub-id pub-id-type="pmid">26502920</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Stevenson, J. C. et al. Use of different transmission metrics to describe malaria epidemiology in the highlands of western Kenya. <italic>Malar. J.</italic><bold>14</bold>, 418 (2015).<pub-id pub-id-type="pmid">26502920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Tusting</surname><given-names>LS</given-names></name><name><surname>Bousema</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name></person-group><article-title>Measuring changes in <italic>Plasmodium Falciparum</italic> transmission: precision, accuracy and costs of metrics</article-title><source>Adv. Parasitol.</source><year>2014</year><volume>84</volume><fpage>151</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-800099-1.00003-X</pub-id><pub-id pub-id-type="pmid">24480314</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tusting, L. S., Bousema, T., Smith, D. L. &#x00026; Drakeley, C. Measuring changes in <italic>Plasmodium Falciparum</italic> transmission: precision, accuracy and costs of metrics. <italic>Adv. Parasitol.</italic><bold>84</bold>, 151&#x02013;208 (2014).<pub-id pub-id-type="pmid">24480314</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>L</given-names></name><etal/></person-group><article-title>Rapid assessment of malaria transmission using age-specific sero-conversion rates</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><issue>6</issue><fpage>e6083</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0006083</pub-id><pub-id pub-id-type="pmid">19562032</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Stewart, L. et al. Rapid assessment of malaria transmission using age-specific sero-conversion rates. <italic>PLoS One</italic>. <bold>4</bold> (6), e6083 (2009).<pub-id pub-id-type="pmid">19562032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Standardizing operational vector sampling techniques for measuring malaria transmission intensity: evaluation of six mosquito collection methods in western Kenya</article-title><source>Malar. J.</source><year>2013</year><volume>12</volume><fpage>143</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-12-143</pub-id><pub-id pub-id-type="pmid">23631641</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wong, J. et al. Standardizing operational vector sampling techniques for measuring malaria transmission intensity: evaluation of six mosquito collection methods in western Kenya. <italic>Malar. J.</italic><bold>12</bold>, 143 (2013).<pub-id pub-id-type="pmid">23631641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>RC</given-names><suffix>Jr</suffix></name><name><surname>Geary</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>PM</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name></person-group><article-title>Seasonality of <italic>Plasmodium Falciparum</italic> transmission: a systematic review</article-title><source>Malar. J.</source><year>2015</year><volume>14</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0849-2</pub-id><pub-id pub-id-type="pmid">26370142</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Reiner, R. C. Jr., Geary, M., Atkinson, P. M., Smith, D. L. &#x00026; Gething, P. W. Seasonality of <italic>Plasmodium Falciparum</italic> transmission: a systematic review. <italic>Malar. J.</italic><bold>14</bold>, 343 (2015).<pub-id pub-id-type="pmid">26370142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Plucinski</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Posttreatment HRP2 clearance in patients with uncomplicated <italic>Plasmodium Falciparum</italic> Malaria</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>217</volume><issue>5</issue><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix622</pub-id><pub-id pub-id-type="pmid">29220497</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Plucinski, M. M. et al. Posttreatment HRP2 clearance in patients with uncomplicated <italic>Plasmodium Falciparum</italic> Malaria. <italic>J. Infect. Dis.</italic><bold>217</bold> (5), 685&#x02013;692 (2018).<pub-id pub-id-type="pmid">29220497</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Plucinski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Malaria surveys using rapid diagnostic tests and validation of results using post hoc quantification of Plasmodium Falciparum histidine-rich protein 2</article-title><source>Malar. J.</source><year>2017</year><volume>16</volume><issue>1</issue><fpage>451</fpage><pub-id pub-id-type="doi">10.1186/s12936-017-2101-8</pub-id><pub-id pub-id-type="pmid">29115966</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Plucinski, M. et al. Malaria surveys using rapid diagnostic tests and validation of results using post hoc quantification of Plasmodium Falciparum histidine-rich protein 2. <italic>Malar. J.</italic><bold>16</bold> (1), 451 (2017).<pub-id pub-id-type="pmid">29115966</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Breman</surname><given-names>JG</given-names></name></person-group><article-title>The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2001</year><volume>64</volume><issue>1&#x02013;2 Suppl</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.64.1</pub-id><pub-id pub-id-type="pmid">11425172</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Breman, J. G. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. <italic>Am. J. Trop. Med. Hyg.</italic><bold>64</bold> (1&#x02013;2 Suppl), 1&#x02013;11 (2001).<pub-id pub-id-type="pmid">11425172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Plucinski</surname><given-names>M</given-names></name><name><surname>Aidoo</surname><given-names>M</given-names></name><name><surname>Rogier</surname><given-names>E</given-names></name></person-group><article-title>Laboratory Detection of Malaria antigens: a strong Tool for Malaria Research, diagnosis, and Epidemiology</article-title><source>Clin. Microbiol. Rev.</source><year>2021</year><volume>34</volume><issue>3</issue><fpage>e0025020</fpage><pub-id pub-id-type="doi">10.1128/CMR.00250-20</pub-id><pub-id pub-id-type="pmid">34043447</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Plucinski, M., Aidoo, M. &#x00026; Rogier, E. Laboratory Detection of Malaria antigens: a strong Tool for Malaria Research, diagnosis, and Epidemiology. <italic>Clin. Microbiol. Rev.</italic><bold>34</bold> (3), e0025020 (2021).<pub-id pub-id-type="pmid">34043447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Ondigo</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple <italic>Plasmodium falciparum</italic> antigens</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>210</volume><issue>7</issue><fpage>1123</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu225</pub-id><pub-id pub-id-type="pmid">24737801</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ondigo, B. N. et al. Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple <italic>Plasmodium falciparum</italic> antigens. <italic>J. Infect. Dis.</italic><bold>210</bold> (7), 1123&#x02013;1132 (2014).<pub-id pub-id-type="pmid">24737801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission intensities in Western Kenya</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>16821</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17084-9</pub-id><pub-id pub-id-type="pmid">29203846</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Weber, G. E. et al. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission intensities in Western Kenya. <italic>Sci. Rep.</italic><bold>7</bold> (1), 16821 (2017).<pub-id pub-id-type="pmid">29203846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Corran</surname><given-names>P</given-names></name><name><surname>Coleman</surname><given-names>P</given-names></name><name><surname>Riley</surname><given-names>E</given-names></name><name><surname>Drakeley</surname><given-names>C</given-names></name></person-group><article-title>Serology: a robust indicator of malaria transmission intensity?</article-title><source>Trends Parasitol.</source><year>2007</year><volume>23</volume><issue>12</issue><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2007.08.023</pub-id><pub-id pub-id-type="pmid">17988945</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Corran, P., Coleman, P., Riley, E. &#x00026; Drakeley, C. Serology: a robust indicator of malaria transmission intensity? <italic>Trends Parasitol.</italic><bold>23</bold> (12), 575&#x02013;582 (2007).<pub-id pub-id-type="pmid">17988945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Drakeley, C., Cook, J. &#x00026; Chapter 5. Potential contribution of sero-epidemiological analysis for monitoring malaria control and elimination: historical and current perspectives. Adv Parasitol ; 69: 299&#x02013;352. (2009).</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Helb</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Novel serologic biomarkers provide accurate estimates of recent <italic>Plasmodium falciparum</italic> exposure for individuals and communities</article-title><source>Proc. Natl. Acad. Sci. U S A</source><year>2015</year><volume>112</volume><issue>32</issue><fpage>E4438</fpage><lpage>E4447</lpage><pub-id pub-id-type="doi">10.1073/pnas.1501705112</pub-id><pub-id pub-id-type="pmid">26216993</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Helb, D. A. et al. Novel serologic biomarkers provide accurate estimates of recent <italic>Plasmodium falciparum</italic> exposure for individuals and communities. <italic>Proc. Natl. Acad. Sci. U S A</italic>. <bold>112</bold> (32), E4438&#x02013;E4447 (2015).<pub-id pub-id-type="pmid">26216993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Akpogheneta</surname><given-names>OJ</given-names></name><etal/></person-group><article-title>Duration of naturally acquired antibody responses to blood-stage <italic>Plasmodium Falciparum</italic> is age dependent and antigen specific</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><issue>4</issue><fpage>1748</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1128/IAI.01333-07</pub-id><pub-id pub-id-type="pmid">18212081</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Akpogheneta, O. J. et al. Duration of naturally acquired antibody responses to blood-stage <italic>Plasmodium Falciparum</italic> is age dependent and antigen specific. <italic>Infect. Immun.</italic><bold>76</bold> (4), 1748&#x02013;1755 (2008).<pub-id pub-id-type="pmid">18212081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Crompton</surname><given-names>PD</given-names></name><etal/></person-group><article-title>A prospective analysis of the ab response to <italic>Plasmodium Falciparum</italic> before and after a malaria season by protein microarray</article-title><source>Proc. Natl. Acad. Sci. U S A</source><year>2010</year><volume>107</volume><issue>15</issue><fpage>6958</fpage><lpage>6963</lpage><pub-id pub-id-type="doi">10.1073/pnas.1001323107</pub-id><pub-id pub-id-type="pmid">20351286</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Crompton, P. D. et al. A prospective analysis of the ab response to <italic>Plasmodium Falciparum</italic> before and after a malaria season by protein microarray. <italic>Proc. Natl. Acad. Sci. U S A</italic>. <bold>107</bold> (15), 6958&#x02013;6963 (2010).<pub-id pub-id-type="pmid">20351286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Stanisic</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Acquisition of antibodies against <italic>Plasmodium Falciparum</italic> merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><issue>2</issue><fpage>646</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1128/IAI.02398-14</pub-id><pub-id pub-id-type="pmid">25422270</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Stanisic, D. I. et al. Acquisition of antibodies against <italic>Plasmodium Falciparum</italic> merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. <italic>Infect. Immun.</italic><bold>83</bold> (2), 646&#x02013;660 (2015).<pub-id pub-id-type="pmid">25422270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Langhorne</surname><given-names>J</given-names></name><name><surname>Ndungu</surname><given-names>FM</given-names></name><name><surname>Sponaas</surname><given-names>AM</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name></person-group><article-title>Immunity to malaria: more questions than answers</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><issue>7</issue><fpage>725</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1038/ni.f.205</pub-id><pub-id pub-id-type="pmid">18563083</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Langhorne, J., Ndungu, F. M., Sponaas, A. M. &#x00026; Marsh, K. Immunity to malaria: more questions than answers. <italic>Nat. Immunol.</italic><bold>9</bold> (7), 725&#x02013;732 (2008).<pub-id pub-id-type="pmid">18563083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sero-epidemiological evaluation of malaria transmission in the Gambia before and after mass drug administration</article-title><source>BMC Med.</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>331</fpage><pub-id pub-id-type="doi">10.1186/s12916-020-01785-6</pub-id><pub-id pub-id-type="pmid">33183292</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wu, L. et al. Sero-epidemiological evaluation of malaria transmission in the Gambia before and after mass drug administration. <italic>BMC Med.</italic><bold>18</bold> (1), 331 (2020).<pub-id pub-id-type="pmid">33183292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Rogier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Bead-based immunoassay allows sub-picogram detection of histidine-rich protein 2 from <italic>Plasmodium Falciparum</italic> and estimates reliability of malaria rapid diagnostic tests</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>2</issue><fpage>e0172139</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0172139</pub-id><pub-id pub-id-type="pmid">28192523</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Rogier, E. et al. Bead-based immunoassay allows sub-picogram detection of histidine-rich protein 2 from <italic>Plasmodium Falciparum</italic> and estimates reliability of malaria rapid diagnostic tests. <italic>PLoS One</italic>. <bold>12</bold> (2), e0172139 (2017).<pub-id pub-id-type="pmid">28192523</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname><given-names>R</given-names></name><etal/></person-group><article-title>Considerations for quality assurance of multiplex malaria antigen detection assays with large sample sets</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>13248</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-92723-w</pub-id><pub-id pub-id-type="pmid">34168264</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Alvarado, R. et al. Considerations for quality assurance of multiplex malaria antigen detection assays with large sample sets. <italic>Sci. Rep.</italic><bold>11</bold> (1), 13248 (2021).<pub-id pub-id-type="pmid">34168264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gwyn</surname><given-names>S</given-names></name><etal/></person-group><article-title>Precision of Serologic Testing from dried blood spots using a multiplex bead assay</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2021</year><volume>105</volume><issue>3</issue><fpage>822</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.21-0140</pub-id><pub-id pub-id-type="pmid">34255738</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gwyn, S. et al. Precision of Serologic Testing from dried blood spots using a multiplex bead assay. <italic>Am. J. Trop. Med. Hyg.</italic><bold>105</bold> (3), 822&#x02013;827 (2021).<pub-id pub-id-type="pmid">34255738</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Iriemenam</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Validation of xMAP SARS-CoV-2 Multi-antigen IgG assay in Nigeria</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><issue>4</issue><fpage>e0266184</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0266184</pub-id><pub-id pub-id-type="pmid">35363818</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Iriemenam, N. C. et al. Validation of xMAP SARS-CoV-2 Multi-antigen IgG assay in Nigeria. <italic>PLoS One</italic>. <bold>17</bold> (4), e0266184 (2022).<pub-id pub-id-type="pmid">35363818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Rogier</surname><given-names>E</given-names></name><etal/></person-group><article-title>High-throughput malaria serosurveillance using a one-step multiplex bead assay</article-title><source>Malar. J.</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>402</fpage><pub-id pub-id-type="doi">10.1186/s12936-019-3027-0</pub-id><pub-id pub-id-type="pmid">31801556</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rogier, E. et al. High-throughput malaria serosurveillance using a one-step multiplex bead assay. <italic>Malar. J.</italic><bold>18</bold> (1), 402 (2019).<pub-id pub-id-type="pmid">31801556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Research priorities for the development and implementation of serological tools for malaria surveillance</article-title><source>F1000Prime Rep.</source><year>2014</year><volume>6</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.12703/P6-100</pub-id><pub-id pub-id-type="pmid">25580254</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Elliott, S. R. et al. Research priorities for the development and implementation of serological tools for malaria surveillance. <italic>F1000Prime Rep.</italic><bold>6</bold>, 100 (2014).<pub-id pub-id-type="pmid">25580254</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Federal Ministry of Health Nigeria. Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2018: technical Report. (2019).</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>C</given-names></name><etal/></person-group><article-title>Non-falciparum malaria infection and IgG seroprevalence among children under 15 years in Nigeria, 2018</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>1360</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37010-0</pub-id><pub-id pub-id-type="pmid">36914649</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Herman, C. et al. Non-falciparum malaria infection and IgG seroprevalence among children under 15 years in Nigeria, 2018. <italic>Nat. Commun.</italic><bold>14</bold> (1), 1360 (2023).<pub-id pub-id-type="pmid">36914649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Oviedo</surname><given-names>A</given-names></name><etal/></person-group><article-title><italic>Plasmodium falciparum</italic> infection prevalence among children aged 6&#x02013;59 months from independent DHS and HIV surveys: Nigeria, 2018</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>1998</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-28257-0</pub-id><pub-id pub-id-type="pmid">36737630</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Oviedo, A. et al. <italic>Plasmodium falciparum</italic> infection prevalence among children aged 6&#x02013;59 months from independent DHS and HIV surveys: Nigeria, 2018. <italic>Sci. Rep.</italic><bold>13</bold> (1), 1998 (2023).<pub-id pub-id-type="pmid">36737630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Aliyu</surname><given-names>GG</given-names></name><etal/></person-group><article-title>The Burden of HIV, Hepatitis B and Hepatitis C by Armed Conflict setting: the Nigeria AIDS Indicator and Impact Survey, 2018</article-title><source>Ann. Glob Health</source><year>2021</year><volume>87</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.5334/aogh.3226</pub-id><pub-id pub-id-type="pmid">34221906</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Aliyu, G. G. et al. The Burden of HIV, Hepatitis B and Hepatitis C by Armed Conflict setting: the Nigeria AIDS Indicator and Impact Survey, 2018. <italic>Ann. Glob Health</italic>. <bold>87</bold> (1), 53 (2021).<pub-id pub-id-type="pmid">34221906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">United Nations &#x02013;&#x02009;2022 Revision of World Population Prospects. <ext-link ext-link-type="uri" xlink:href="https://population.un.org/wpp/">https://population.un.org/wpp/</ext-link>. Accessed 11/12/2023.</mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">ICF NPC-NNa. <italic>Nigeria Demographic and Health Survey 2018. Abuja, Nigeria, and Rockville</italic> (NPC and ICF., 2019).</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">National Malaria Elimination Programme (NMEP). <italic>NPCN, National Bureau of Statistics (NBS), and ICF International. Nigeria Malaria Indicator Survey 2015</italic> (Abuja, Nigeria, and Rockville, 2016).</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Okunlola</surname><given-names>OA</given-names></name><name><surname>Oyeyemi</surname><given-names>OT</given-names></name></person-group><article-title>Spatio-temporal analysis of association between incidence of malaria and environmental predictors of malaria transmission in Nigeria</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>17500</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-53814-x</pub-id><pub-id pub-id-type="pmid">31767899</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Okunlola, O. A. &#x00026; Oyeyemi, O. T. Spatio-temporal analysis of association between incidence of malaria and environmental predictors of malaria transmission in Nigeria. <italic>Sci. Rep.</italic><bold>9</bold> (1), 17500 (2019).<pub-id pub-id-type="pmid">31767899</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Nigeria, H. I. V. A. I. D. S. Indicator and Impact Survey (NAIIS) 2018, 2019 05/01/2023.</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Jahun</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evaluation of accuracy and performance of self-reported HIV and antiretroviral therapy status in the Nigeria AIDS Indicator and Impact Survey (2018)</article-title><source>PLoS One</source><year>2022</year><volume>17</volume><issue>8</issue><fpage>e0273748</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0273748</pub-id><pub-id pub-id-type="pmid">36037201</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Jahun, I. et al. Evaluation of accuracy and performance of self-reported HIV and antiretroviral therapy status in the Nigeria AIDS Indicator and Impact Survey (2018). <italic>PLoS One</italic>. <bold>17</bold> (8), e0273748 (2022).<pub-id pub-id-type="pmid">36037201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Jahun</surname><given-names>I</given-names></name><etal/></person-group><article-title>Optimizing community linkage to care and antiretroviral therapy initiation: lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><issue>9</issue><fpage>e0257476</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0257476</pub-id><pub-id pub-id-type="pmid">34543306</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Jahun, I. et al. Optimizing community linkage to care and antiretroviral therapy initiation: lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. <italic>PLoS One</italic>. <bold>16</bold> (9), e0257476 (2021).<pub-id pub-id-type="pmid">34543306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Salihu</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Development of a Quality Assurance score for the Nigeria AIDS Indicator and Impact Survey (NAIIS) database: Validation Study</article-title><source>JMIR Form. Res.</source><year>2022</year><volume>6</volume><issue>1</issue><fpage>e25752</fpage><pub-id pub-id-type="doi">10.2196/25752</pub-id><pub-id pub-id-type="pmid">35089143</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Salihu, H. M. et al. Development of a Quality Assurance score for the Nigeria AIDS Indicator and Impact Survey (NAIIS) database: Validation Study. <italic>JMIR Form. Res.</italic><bold>6</bold> (1), e25752 (2022).<pub-id pub-id-type="pmid">35089143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Plucinski</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique</article-title><source>PLoS Negl. Trop. Dis.</source><year>2018</year><volume>12</volume><issue>2</issue><fpage>e0006278</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006278</pub-id><pub-id pub-id-type="pmid">29444078</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Plucinski, M. M. et al. Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. <italic>PLoS Negl. Trop. Dis.</italic><bold>12</bold> (2), e0006278 (2018).<pub-id pub-id-type="pmid">29444078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Dynamics of IgG antibody response against <italic>Plasmodium</italic> antigens among Nigerian infants and young children</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1208822</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1208822</pub-id><pub-id pub-id-type="pmid">37691957</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Leonard, C. M. et al. Dynamics of IgG antibody response against <italic>Plasmodium</italic> antigens among Nigerian infants and young children. <italic>Front. Immunol.</italic><bold>14</bold>, 1208822 (2023).<pub-id pub-id-type="pmid">37691957</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Priest</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Integration of Multiplex bead assays for parasitic diseases into a National, Population-based Serosurvey of women 15&#x02013;39 years of age in Cambodia</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><issue>5</issue><fpage>e0004699</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0004699</pub-id><pub-id pub-id-type="pmid">27136913</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Priest, J. W. et al. Integration of Multiplex bead assays for parasitic diseases into a National, Population-based Serosurvey of women 15&#x02013;39 years of age in Cambodia. <italic>PLoS Negl. Trop. Dis.</italic><bold>10</bold> (5), e0004699 (2016).<pub-id pub-id-type="pmid">27136913</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Rogier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Multiple comparisons analysis of serological data from an area of low <italic>Plasmodium Falciparum</italic> transmission</article-title><source>Malar. J.</source><year>2015</year><volume>14</volume><fpage>436</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0955-1</pub-id><pub-id pub-id-type="pmid">26537125</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Rogier, E. et al. Multiple comparisons analysis of serological data from an area of low <italic>Plasmodium Falciparum</italic> transmission. <italic>Malar. J.</italic><bold>14</bold>, 436 (2015).<pub-id pub-id-type="pmid">26537125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerkhof</surname><given-names>K</given-names></name><etal/></person-group><article-title>Implementation and application of a multiplex assay to detect malaria-specific antibodies: a promising tool for assessing malaria transmission in southeast Asian pre-elimination areas</article-title><source>Malar. J.</source><year>2015</year><volume>14</volume><fpage>338</fpage><pub-id pub-id-type="doi">10.1186/s12936-015-0868-z</pub-id><pub-id pub-id-type="pmid">26337785</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kerkhof, K. et al. Implementation and application of a multiplex assay to detect malaria-specific antibodies: a promising tool for assessing malaria transmission in southeast Asian pre-elimination areas. <italic>Malar. J.</italic><bold>14</bold>, 338 (2015).<pub-id pub-id-type="pmid">26337785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Priest</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Specificity of the IgG antibody response to <italic>Plasmodium Falciparum, Plasmodium Vivax, Plasmodium malariae</italic>, and <italic>Plasmodium ovale</italic> MSP1(19) subunit proteins in multiplexed serologic assays</article-title><source>Malar. J.</source><year>2018</year><volume>17</volume><issue>1</issue><fpage>417</fpage><pub-id pub-id-type="doi">10.1186/s12936-018-2566-0</pub-id><pub-id pub-id-type="pmid">30413163</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Priest, J. W. et al. Specificity of the IgG antibody response to <italic>Plasmodium Falciparum, Plasmodium Vivax, Plasmodium malariae</italic>, and <italic>Plasmodium ovale</italic> MSP1(19) subunit proteins in multiplexed serologic assays. <italic>Malar. J.</italic><bold>17</bold> (1), 417 (2018).<pub-id pub-id-type="pmid">30413163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Bousema</surname><given-names>T</given-names></name><etal/></person-group><article-title>Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008</article-title><source>Emerg. Infect. Dis.</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.3201/eid1603.090732</pub-id><pub-id pub-id-type="pmid">20202412</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bousema, T. et al. Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. <italic>Emerg. Infect. Dis.</italic><bold>16</bold> (3), 392&#x02013;399 (2010).<pub-id pub-id-type="pmid">20202412</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Rogier</surname><given-names>E</given-names></name><etal/></person-group><article-title>Framework for characterizing longitudinal antibody response in children after <italic>Plasmodium falciparum</italic> infection</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>617951</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.617951</pub-id><pub-id pub-id-type="pmid">33737926</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Rogier, E. et al. Framework for characterizing longitudinal antibody response in children after <italic>Plasmodium falciparum</italic> infection. <italic>Front. Immunol.</italic><bold>12</bold>, 617951 (2021).<pub-id pub-id-type="pmid">33737926</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Drakeley</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure</article-title><source>Proc. Natl. Acad. Sci. U S A</source><year>2005</year><volume>102</volume><issue>14</issue><fpage>5108</fpage><lpage>5113</lpage><pub-id pub-id-type="doi">10.1073/pnas.0408725102</pub-id><pub-id pub-id-type="pmid">15792998</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Drakeley, C. J. et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. <italic>Proc. Natl. Acad. Sci. U S A</italic>. <bold>102</bold> (14), 5108&#x02013;5113 (2005).<pub-id pub-id-type="pmid">15792998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Otsu</surname><given-names>N</given-names></name></person-group><article-title>A threshold selection method from gray-level histograms</article-title><source>IEEE Trans. Syst. man. Cybernetics</source><year>1979</year><volume>9</volume><issue>1</issue><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1109/TSMC.1979.4310076</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Otsu, N. A threshold selection method from gray-level histograms. <italic>IEEE Trans. Syst. man. Cybernetics</italic>. <bold>9</bold> (1), 62&#x02013;66 (1979).</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Rangu</surname><given-names>S</given-names></name><name><surname>Veramalla</surname><given-names>R</given-names></name><name><surname>Salkuti</surname><given-names>SR</given-names></name><name><surname>Kalagadda</surname><given-names>B</given-names></name></person-group><article-title>Efficient approach to color image segmentation based on multilevel thresholding using EMO algorithm by considering spatial contextual information</article-title><source>J. Imaging.</source><year>2023</year><volume>9</volume><issue>4</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.3390/jimaging9040074</pub-id><pub-id pub-id-type="pmid">37103225</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Rangu, S., Veramalla, R., Salkuti, S. R. &#x00026; Kalagadda, B. Efficient approach to color image segmentation based on multilevel thresholding using EMO algorithm by considering spatial contextual information. <italic>J. Imaging.</italic><bold>9</bold>(4), 74 (2023).<pub-id pub-id-type="pmid">37103225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Kurita</surname><given-names>T</given-names></name><name><surname>Otsu</surname><given-names>N</given-names></name><name><surname>Abdelmalek</surname><given-names>NN</given-names></name></person-group><article-title>Maximum likelihood thresholding based on population mixture models</article-title><source>Pattern Recognit.</source><year>1992</year><volume>25</volume><fpage>1231</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1016/0031-3203(92)90024-D</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kurita, T., Otsu, N. &#x00026; Abdelmalek, N. N. Maximum likelihood thresholding based on population mixture models. <italic>Pattern Recognit.</italic><bold>25</bold>, 1231&#x02013;1240 (1992).</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>JH</given-names></name><name><surname>Titterington</surname><given-names>DM</given-names></name><name><surname>t-Tests</surname></name></person-group><article-title>F-tests and Otsu&#x02019;s methods for image thresholding</article-title><source>IEEE Trans. Image Process.</source><year>2011</year><volume>20</volume><issue>8</issue><fpage>2392</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.1109/TIP.2011.2114358</pub-id><pub-id pub-id-type="pmid">21324779</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Xue, J. H., Titterington, D. M. &#x00026; t-Tests F-tests and Otsu&#x02019;s methods for image thresholding. <italic>IEEE Trans. Image Process.</italic><bold>20</bold> (8), 2392&#x02013;2396 (2011).<pub-id pub-id-type="pmid">21324779</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kinyanjui</surname><given-names>SM</given-names></name><name><surname>Conway</surname><given-names>DJ</given-names></name><name><surname>Lanar</surname><given-names>DE</given-names></name><name><surname>Marsh</surname><given-names>K</given-names></name></person-group><article-title>IgG antibody responses to <italic>Plasmodium Falciparum</italic> merozoite antigens in Kenyan children have a short half-life</article-title><source>Malar. J.</source><year>2007</year><volume>6</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/1475-2875-6-82</pub-id><pub-id pub-id-type="pmid">17598897</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kinyanjui, S. M., Conway, D. J., Lanar, D. E. &#x00026; Marsh, K. IgG antibody responses to <italic>Plasmodium Falciparum</italic> merozoite antigens in Kenyan children have a short half-life. <italic>Malar. J.</italic><bold>6</bold>, 82 (2007).<pub-id pub-id-type="pmid">17598897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Dent</surname><given-names>AE</given-names></name><etal/></person-group><article-title><italic>Plasmodium falciparum</italic> Prmicroarrayoantibodytprofilesocorrelaterwithe With Protefromn From Symptomatic Malaria in Kenya</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><issue>9</issue><fpage>1429</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv224</pub-id><pub-id pub-id-type="pmid">25883384</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Dent, A. E. et al. <italic>Plasmodium falciparum</italic> Prmicroarrayoantibodytprofilesocorrelaterwithe With Protefromn From Symptomatic Malaria in Kenya. <italic>J. Infect. Dis.</italic><bold>212</bold> (9), 1429&#x02013;1438 (2015).<pub-id pub-id-type="pmid">25883384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Fowkes</surname><given-names>FJ</given-names></name><name><surname>Boeuf</surname><given-names>P</given-names></name><name><surname>Beeson</surname><given-names>JG</given-names></name></person-group><article-title>Immunity to malaria in an era of declining malaria transmission</article-title><source>Parasitology</source><year>2016</year><volume>143</volume><issue>2</issue><fpage>139</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1017/S0031182015001249</pub-id><pub-id pub-id-type="pmid">26741253</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Fowkes, F. J., Boeuf, P. &#x00026; Beeson, J. G. Immunity to malaria in an era of declining malaria transmission. <italic>Parasitology</italic>. <bold>143</bold> (2), 139&#x02013;153 (2016).<pub-id pub-id-type="pmid">26741253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Tassi Yunga</surname><given-names>S</given-names></name><etal/></person-group><article-title>Characterization of the primary antibody response to <italic>Plasmodium falciparum</italic> antigens in infants living in a malaria-endemic area</article-title><source>Malar. J.</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>346</fpage><pub-id pub-id-type="doi">10.1186/s12936-022-04360-x</pub-id><pub-id pub-id-type="pmid">36403045</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Tassi Yunga, S. et al. Characterization of the primary antibody response to <italic>Plasmodium falciparum</italic> antigens in infants living in a malaria-endemic area. <italic>Malar. J.</italic><bold>21</bold> (1), 346 (2022).<pub-id pub-id-type="pmid">36403045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Mugo</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children</article-title><source>Malar. J.</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>452</fpage><pub-id pub-id-type="doi">10.1186/s12936-021-03961-2</pub-id><pub-id pub-id-type="pmid">34856981</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Mugo, R. M. et al. Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children. <italic>Malar. J.</italic><bold>20</bold> (1), 452 (2021).<pub-id pub-id-type="pmid">34856981</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>